Atazanavir

ARV U.S. Brand Name

Reyataz

ARV Abbreviation(s)

ATV

U.S. FDA Label

Atazanavir Labeling (Package Insert)

ARV Class

Protease Inhibitors

First U.S. Approval

December 19, 2014

U.S. Manufacturer

Bristol Myers Squibb

Formulations

Strength	Formulation	Image	Description	Boosted
150 mg	Capsules	X	Blue and Aqua oblong Capsule with BMS 150 mg, and 3624 imprinted	No
200 mg	Capsules	X	Blue oblong Capsule with BMS 200 mg, and 3631 imprinted	No
300 mg	Capsules	X	Red and Blue Capsule with BMS 300 mg imprinted	No
300 mg of atazanavir and 150 mg of cobicistat	Tablet	X	Oval, biconvex, pink, film-coated, debossed with “3641” on one side and plain on the other side	Yes

Generic Available?

Yes

Other Reference Links

Clinical Info HIV Drug Database (ATV)

National HIV Curriculum (Atazanavir)

Clinical Info HIV Drug Database (ATV/COBI)

National HIV Curriculum (Atazanavir-Cobicistat)

FDCs

Atazanavir / Cobicistat

Displaying 101 - 140 of 140

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Atazanavir RFB 768	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin		Atazanavir Cmax increased 34%	150 mg daily on days 15-28	Not reported	Use rifabutin 150 mg once daily or 300 mg three times a week. Monitor for antimycobacterial activity and consider therapeutic drug monitoring.
Atazanavir RFB 767	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Potential increase in atazanavir adverse effects	Atazanavir AUC increased 191%, Cmax increased 81%	150 mg daily on days 15-28	Not reported	Use rifabutin 150 mg once daily or 300 mg three times a week. Monitor for antimycobacterial activity and consider therapeutic drug monitoring.
Atazanavir RFB 766	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Increased rifabutin effects (eg, uveitis)	Not reported	300 mg daily on days 1-10, then 150 mg daily on days 11-20	Rifabutin AUC increased 110%, Cmax increased 118%, Cmin increased 243%, 25-O-desacetylrifabutin AUC increased 2101%, Cmax increased 720%, Cmin increased 7460%	Use rifabutin 150 mg once daily or 300 mg three times a week. Monitor for antimycobacterial activity and consider therapeutic drug monitoring.
Atazanavir Pitavastatin 765	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of pitavastatin	Potential for increased pitavastatin adverse effects	No significant change	4 mg daily	Pitavastatin AUC increased 31%, Cmax increased 60%	Start at lowest dose and titrate to effect
Atazanavir MVC 764	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential increase in maraviroc adverse effects	Not reported	300 mg BID	Maraviroc AUC increased 388%, Cmax increased 167%, Cmin increased 567%	Decrease maraviroc dose to 150 mg BID
Atazanavir MVC 763	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential increase in maraviroc adverse effects	Not reported	300 mg BID	Maraviroc AUC increased 257%, Cmax increased 109%, Cmin increased 319%	Decrease maraviroc dose to 150 mg BID
Atazanavir Itraconazole 762	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of itraconazole					Unless guided by therapeutic drug monitoring, limit doses of itraconazole to less than 200 mg daily when used with atazanavir / cobicistat.
Atazanavir Ethinyl estradiol / Norethindrone acetate 761	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of hormonal contraception	Increased norethindrone and ethinyl estradiol effects		1 tab daily (7 / 7 / 7)	Norethindrone Cmax increased 67%, AUC increased 110%, Cmin increased 262%, Ethinyl estradiol AUC increased 48%, Cmax no significant change, Cmin increased 91%	For unboosted atazanavir, use an oral contraceptive that contains no more than 30 mcg of ethinyl estradiol or recommend an alternative contraceptive method. Oral contraceptives containing less than 25mcg of ethinyl estradiol or progestins other than norethindrone or norgestimate have not been studied.
Atazanavir Diltiazem 760	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of diltiazem	Potential for increased diltiazem effects (eg, hypotension, heart block)	No significant change	180 mg daily on days 7-11 and 19-23	Diltiazem AUC increased 125%, Cmax increased 198%, Cmin decreased 59%	Reduce diltiazem dose by 50%. ECG monitoring is recommended.
Atazanavir Daclatasvir 759	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of daclatasvir		No significant change	20 mg daily	AUC(tau) increased 110%	Decrease daclatasvir dose to 30 mg daily when used with atazanavir / ritonavir. No dose adjustment necessary if used with unboosted atazanavir.
Atazanavir Daclatasvir 758	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of daclatasvir					Decrease daclatasvir dose to 30 mg daily
Atazanavir Colchicine 757	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of colchicine	Potential for increased colchicine effects				For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Dose should not be repeated earlier than 3 days after. For gout prophylaxis, reduce colchicine dose to 0.3 mg daily if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg every other day if on 0.6 mg daily prior to PI therapy. For treatment of familial Mediterranean fever do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Do not coadminister in patients with hepatic or renal impairment.
Atazanavir Clarithromycin 756	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of clarithromycin	Potential for increased clarithromycin effects. (e.g. may cause QTc prolongation).	Atazanavir AUC increased 28%, Cmax no significant change, Cmin increased 91%	500 mg BID on days 7-11 and 18-21	Clarithromycin AUC increased 94%, Cmax increased 50%, Cmin decreased 62%, 14-hydroxyclarithromycin AUC decreased 70%, Cmax decreased 72%, Cmin increased 164%	Reduce clarithromycin dose by 50%
Atazanavir RTV 755	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atazanavir	Increased atazanavir effects	Atazanavir AUC increased 238%; Cmax increased 86%; Cmin increased 1089%	100 mg daily on days 11-20	Not studied	Dose atazanavir 300 mg once daily with ritonavir 100 mg daily
Atazanavir DRV 754	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of antiretrovirals		Atazanavir Cmin increased 52%	400 mg BID with ritonavir 100 mg BID	No significant change	If used in combination, atazanavir may be given in conjunction with darunavir / ritonavir at study doses (300mg daily plus 400 / 100 mg daily)
Tenofovir disoproxil fumarate ATV 728	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Increased tenofovir effects, decreased atazanavir effects	Cmax increase 34%, AUC increase 37%, Cmin increase 29%	300 mg once daily with 100 mg ritonavir daily	Cmax decrease 28%, AUC decrease 25%, Cmin decrease 23%	Do not coadminister with unboosted atazanavir (400 mg). Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. If coadministering atazanavir, ritonavir, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg (plus 100 mg ritonavir).
Tenofovir disoproxil fumarate ATV 727	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Increased tenofovir effects, decreased atazanavir effects	Cmax increase 14%, AUC increase 24%, Cmin increase 22%	400 mg once daily with a light meal	Cmax decrease 21%, AUC decrease 25%, Cmin decrease 40%	Do not coadminister with unboosted atazanavir (400 mg). Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. If coadministering atazanavir, ritonavir, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg (plus 100 mg ritonavir).
Tenofovir disoproxil fumarate ATV 726	Yellow: Adjust dosing	Adjust dosing to avoid altered levels of atazanavir and TDF	Increased atazanavir and tenofovir effects	Cmax increase 39%, AUC increase 55%, Cmin increase 70%	400 mg once daily with 100 mg ritonavir daily	Cmax increase 31%, AUC increase 38%, Cmin increase 33%	Do not coadminister with unboosted atazanavir (400 mg). Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen. If coadministering atazanavir, ritonavir, tenofovir, and an H2 receptor antagonist in a treatment-experienced patient, increase atazanavir dose to 400 mg (plus 100 mg ritonavir).
Tenofovir alafenamide ATV 703	Green: Administer standard doses	Administer standard doses		Cmax increased 77%, AUC increased 91%	300 mg + 100mg ritonavir once daily	Cmax decreased 2%, AUC decreased 1%
Lamivudine ATV 699	Green: Administer standard doses	Administer standard doses		No significant change	400 mg daily x 6 days	Not studied
Nevirapine ATV 614	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Decreased atazanavir effects	Not studied	400 mg atazanavir daily with 100 mg ritonavir daily	Atazanavir AUC decreased 19%; Cmax no significant change; Cmin decreased 59%	Use alternative agents
Nevirapine ATV 613	Red: Avoid combination	Do not coadminister: Reduced levels of atazanavir	Decreased atazanavir effects	No significant change	300 mg atazanavir daily with 100 mg ritonavir daily	Atazanavir AUC decreased 42%; Cmax decreased 28%; Cmin decreased 72%	Use alternative agents
Etravirine ATV 574			Potential for increased etravirine effects	Etravirine AUC increased 30%; Cmax increased 30%; Cmin decreased 26%	300 mg daily with 100 mg ritonavir daily	Atazanavir AUC decreased 14%; Cmin decreased 38%	When using atazanavir 300 mg plus ritonavir 100 mg once daily use etravirine standard dose.
Efavirenz ATV 439	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 43%, Cmax increased 17%	Use alternative agents
Efavirenz ATV 438	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		300 mg daily / ritonavir 100 mg daily days 1-10 then 400 mg daily / ritonavir 100 mg daily days 11-24	Atazanavir Cmin decreased 42%, Cmax increased 17%	Use alternative agents
Efavirenz ATV 437	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 48%.	Use alternative agents
Efavirenz ATV 436	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily d 1-6, then 300 mg daily days 7_-20 with ritonavir 100 mg daily	Atazanavir auc increased 39%, Cmax increased 48%, Cmin increased 14%.	Use alternative agents
Efavirenz ATV 435	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily x 20 days	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%.	Use alternative agents
Efavirenz ATV 434	Red: Avoid combination	Do not coadminister: Potential for reduced levels of atazanavir	Potential loss of antiviral efficacy		400 mg daily x 20 days	Atazanavir AUC decreased 74%, Cmax decreased 59%, Cmin decreased 93%.	Use alternative agents
Raltegravir ATV 310	Green: Administer standard doses	Administer standard doses		RAL AUC no significant change	300 mg BID	Not reported
Raltegravir ATV 293	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 72%; Cmax increased 53%; Cmin increased 95%	400 mg daily
Raltegravir ATV 292	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 41%; Cmax increased 24%; Cmin increased 77%	300 mg with 100 mg ritonavir daily
Raltegravir ATV 291	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 67%	400 mg daily	Not reported
Raltegravir ATV 289	Green: Administer standard doses	Administer standard doses	Potential for increased raltegravir effects	Raltegravir AUC increased 54%; Cmin increased 48%; Cmax increased 39%	300 mg BID on days 6-12 and days 13-26	Atazanavir AUC decreased 17%; Cmin decreased 29% (compared to atazanavir BID)
Dolutegravir ATV 109	Green: Administer standard doses	Administer standard doses		Cmax increased 50%, AUC increased 91%, Cmin increased 180%	400 mg once daily	Not studied
Dolutegravir ATV/r 107	Green: Administer standard doses	Administer standard doses		Cmax increased 34%, AUC increased 62%, Cmin increased 121%	300 / 100 mg once daily	Not studied
Maraviroc ATV/r 45	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects	Maraviroc AUC increased 388%; Cmax increased 167%	300 mg / 100 mg daily	Not reported	Reduce dose of maraviroc to 150 mg BID
Maraviroc ATV 44	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects	Maraviroc AUC increased 257%; Cmax increased 109%	400 mg daily	Not reported	Reduce dose of maraviroc to 150 mg BID
Fostemsavir ATV/r 6	Green: Administer standard doses	Administer standard doses		Temsavir Cmax increased 68%, AUC increased 54%, Cmin increased 57%	ATV 300mg, / r 100mg once daily	ATV: Cmax increased 3%, AUC increased 9%, Cmin increased 19%; / r: Cmax increased 2%, AUC increased 7%, Cmin increased 22%
Atazanavir

Subscribe to Atazanavir